Business
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nPreliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025\n\n\n\nConsistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA® by U.S. urologists\n\n\n\nFull-year 2025 net product revenue of $113 million, a 700% increase over full-year 2024, as reported in the Company’s Form 10-K\n\n\n\nANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025\n\n\n\nANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries\n\n\n\nNCCN Clinical Practice Guidelines updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease (Category 2A)\n\n\n\nPivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) fully enrolled, with the Independent Data Monitoring Committee (IDMC) confirming adequate statistical power; supplemental BLA submission on track for 2026\n\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026. ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch, including a 168% increase over Q1 2025. This builds on full-year 2025 net product revenue of $113 million, a 700% increase over full-year 2024. Q1 2026 net product revenue also represents a 15% sequential increase over the $38.3 million earned during Q4 2025.\n\n\nANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries. Additionally, the pivotal BCG-naïve CIS trial (QUILT-2.005) is fully enrolled, with the IDMC confirming no additional enrollment is required. A supplemental BLA submission is on track for 2026.\n\n\nThe Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.\n\n\n“ANKTIVA’s continued momentum reflects growing physician adoption and disciplined commercial execution,” said Richard Adcock, President and CEO of ImmunityBio. “Following strong growth in 2025, w...